About Dermtest


Dermtest empowers general practitioners in fighting melanoma, the deadliest type of skin cancer. Dermtest also brings remote specialist diagnosis and treatment plans for other skin diseases to local GPs. We offer the modern e-health solution for individual doctor practices, clinic networks, health regions, insurances and governments. We are operational in 3 EU countries and Dermtest detection service is locally accessible to 1.5 million people.

dt

 
Developed with experienced dermatologists
Supported by Horizon2020 SME instrument
Modern and secure IT-solution (ePrivacy certified)
Certified dermoscopes
Offices in Berlin and Tallinn (operational in 3 countries)

The core product is a software platform connecting general practitioners with dermatologists, to provide early skin cancer detection service to patients at their local general practitioner's office. The service enables discovering early changes in moles that may develop into malignant skin tumors and react quickly with a treatment plan.

As a solution provider, we combine teledermatology software and diagnostic hardware into a complete work-flow management service, including support, change management and awareness building. With the prevention-oriented solution, we can increase access to care, increase quality and cost-efficiency and reduce melanoma mortality.  

Dermtest started in 2013 as a local telemedicine project for early melanoma detection between 2 GP-offices in rural areas and the largest dermato-oncology clinic in the capital of Estonia. It was developed in close cooperation with experienced dermato-oncologists – all practicing clinicians. In 2014 Dermtest spinned-off into a separate international company for scaling the technology. The system has been presented at a number of clinical conferences including World Congress of Dermoscopy (2015) and World Congress of Teledermatology (2016) and is compliant with data protection regulations in EU - we have been certified by ePrivacy GmbH.

Our team has extensive healthcare experience and we involve different healthcare stakeholders into the implementation process. Platform can be localized in your country in 3 months. If Dermtest is already localized in your country (such as Germany, Lithuania, Estonia) then the service can be started at new primary care clinic in just a few hours.

Do you want to join the fight against melanoma and implement e-health, which really makes sense?

Contact us now:

[email protected] (Priit Kruus, Dermtest CEO)